Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

NYT: President to Request Research Funding for Treatments Tailored to Patients’ DNA

Washington, DC, January 26, 2015 The New York Times’ Robert Pear reports that President Obama will seek hundreds of millions of dollars for a new initiative to develop medical treatments tailored to genetic and other characteristics of individual patients, administration officials say.

The proposal, mentioned briefly in his State of the Union address, will be described in greater detail in his budget in the coming weeks.  The effort is likely to receive support from members of both parties, lawmakers said.

In his address, President Obama called it “precision medicine,” but the terms “personalized medicine” and “individualized medicine” are also widely used to describe the evolving field in which, for example, a doctor prescribes a medication that targets a specific mutation in a patient’s genes.

“This is an incredible area of promise,” said Senator Bill Cassidy, Republican of Louisiana and a gastroenterologist.  “There will be bipartisan support.”

The money would support biomedical research at the National Institutes of Health and the regulation of diagnostic tests by the Food and Drug Administration, officials at the two agencies said.

The tests analyze the DNA in normal or diseased tissue.  Doctors use that information to identify patients with cancer or other diseases who are most likely to benefit from a particular treatment — and those who would be harmed or not respond at all.

The Times also reported that the President’s budget will also propose increased federal spending to combat antibiotic-resistant bacteria.  The plan would nearly double spending from its current level of $450 million a year.

For Mr. Pear’s complete report, click here.